Articles tagged with Sepsis
The article discusses clinical early warning scores as new clinical tools to predict future clinical deterioration, particularly related to sepsis. It provides a critical review of the state-of-the-art in early warning algorithms and suggests further research initiatives.
A commentary suggests using smart technology and artificial intelligence to improve the detection of sepsis in children in Canada. The authors propose automating data combinations of sepsis symptoms and other relevant information to create more accurate and low-cost trigger tools.
A large Taiwanese study found that patients with sepsis are at increased risk of cardiovascular events, including stroke and heart attack, within the first 4 weeks after hospital discharge. Younger patients with sepsis aged 20 to 45 years were particularly at higher risk.
A team of researchers from Case Western Reserve University discovered a way to stop immune cell death associated with multiple diseases, including sepsis, IBD, and arthritis. They identified a chemical, necrosulfonamide, that potently inhibits inflammatory cell death by preventing pyroptosis, a type of cell suicide.
A £2 million project, ARCS, aims to tackle sepsis in Africa by creating sustainable partnerships between research, clinical, and government organizations. The initiative focuses on delivering high-quality training, establishing care quality indicators, and testing innovative interventions.
Researchers at UCalgary discovered the key target of a toxin that worsens sepsis caused by Staphylococcus aureus. The findings suggest an antibody targeting this toxin could prevent platelet aggregation and organ failure, offering new hope for patients in intensive care.
A new analysis shows that completing a sepsis protocol within an hour of detection significantly increases survival rates in children, with completion of all elements required to reduce mortality. The study supports New York's Rory's Regulations mandate and encourages expansion to other states.
Researchers at Columbia University Irving Medical Center found a potential link between microRNAs and sepsis, identifying two molecules that silence inflammatory gene expression. These biomarkers could help diagnose patients at risk of organ failure and death, allowing for faster treatment and potentially saving lives.
The Massachusetts Medical Device Development Center has received a $500,000 grant from BARDA to help startups develop cures for pandemic flu and sepsis. Two startups already working with M2D2 plan to join the new network.
A new study reveals children's immune systems can control infections and prevent sepsis, a disease responsible for more UK deaths than cancer combined. The research identifies key responses in children's cells that help them ward off severe infections.
Researchers have discovered a novel treatment that reduces the deadly immune response triggered by trauma, which can lead to systemic inflammatory response syndrome and sepsis. The drug, deformylase, neutralizes N-formyl peptides released from damaged mitochondria, improving survival rates in animal models.
Immunocompromised patients with sepsis are more likely to die if treated in a hospital caring for a relatively small number of these patients. Hospitals that treat large numbers of immunosuppressed patients with sepsis may improve outcomes, study results suggest.
Researchers at Intermountain Medical Center found that about 16 percent of sepsis patients diagnosed in emergency departments are treated and released for outpatient management. Despite this, these patients have fairly good outcomes, including a similar chance of dying in the following 30 days as admitted patients.
A recent study analyzing over 3.7 million hospital admissions found that overweight and obese patients had a lower risk of dying from sepsis compared to those with normal weight. The study also showed improved survival and reduced readmission rates for these groups.
A recent awareness and management programme for sepsis has led to increased E. coli blood stream infection cases, raising questions about the effectiveness of existing targets. The programme's success in sepsis detection suggests considering alternative measures, such as positive-to-negative sample ratios or urine analysis.
Researchers at Massachusetts General Hospital developed a microfluidic device that measures neutrophil motility to accurately diagnose sepsis. The device achieved more than 95% accuracy in distinguishing patients with sepsis from those without, offering a promising new approach to timely treatment.
Researchers discovered that gut bacteria play a role in brain impairment after sepsis, with certain strains associated with neuroinflammation and cognitive difficulties. The study suggests treating gut bacteria may help reduce long-term effects of critical illness.
Researchers discovered that gut bacteria stimulate serum IgA responses that offer protection against bacterial sepsis. The study found mice with Proteobacteria-rich microbiota survived longer after sepsis, while those without IgA antibodies died quickly.
Scientists used a computational model to show that sepsis treatment needs multiple-step targeting for effective therapy. The study suggests 'precision medicine' is necessary due to the complexity of individual patient responses.
Researchers at Saint Louis University have discovered a link between elevated chlorinated lipids and severe outcomes in sepsis patients. The study found that high levels of these lipids can predict acute respiratory distress syndrome and death within 30 days, suggesting they may serve as an early warning sign of the condition.
Scientists at NUST MISIS have developed a new rapid-test that can accurately diagnose acute myocardial infarction and identify sepsis in just 10 minutes. The test uses immunochromatography principles and detects disease markers in blood, allowing for early treatment intervention.
A recent study found that sepsis kills an alarming 55.7% of ICU patients, with Brazilian ICUs facing low bed availability and inadequate care contributing to the high mortality rate. Vaccination and simple hospital infection-control measures can prevent community- and healthcare-acquired sepsis.
Rutgers New Jersey Medical School immunologist Luis Ulloa believes the body has an electrical network that can be used to manipulate and help control its functions. He suggests phone-based bioelectronic medicine could treat inflammatory disorders like arthritis, colitis, diabetes, obesity, and life-threatening infections.
A UC Riverside-led research team has identified the human protein resistin as a potential treatment for sepsis, boosting survival rates to 100% in a mouse model. By binding to TLR4, resistin blocks inflammatory responses and minimizes immune system overdrive.
A new study suggests that integrated sepsis screening and treatment protocols can increase the use of broad-spectrum antibiotics, leading to higher healthcare facility-onset C. difficile infection (CDI) rates. Researchers found an increased rate of HCFO CDI during and following sepsis care bundle implementation.
New research reveals sepsis disrupts immune system function by impairing TRM recruitment to infected skin, increasing risk of life-threatening secondary infections. In mice, sepsis stymied TRM's ability to recruit bystander T and B cells to fight infection.
A new research study published in JAMA found that sepsis was present in six percent of all hospitalizations and one in three hospitalizations that ended in death. The study used electronic health record data from nearly 3 million patients to estimate the total burden of sepsis nationwide.
Scientists at Temple University Health System uncover the mechanism underlying energy loss from heart dysfunction in sepsis, proposing NOX2 inhibition as a potential treatment. The research builds on earlier findings and aims to provide extra time for anti-inflammatory treatments to work.
A new study published in Scientific Reports found that measuring five key biomarkers in blood can quickly identify patients with sepsis, potentially saving lives. The researchers used machine learning models to determine the predictive power of using traditional vital sign data, biomarkers alone, or a combination of both.
A study found that more than half of heart patients are admitted to the cardiac intensive care unit (CICU) for noncardiac conditions such as sepsis or renal failure. This shift in patient composition requires providers to reassess training and staffing models, with implications for care and outcomes.
Research found a six-fold increased risk of cardiovascular disease in adults hospitalized for pneumonia or sepsis within the first year. Cardiovascular risk remained elevated for at least five years after infection, similar to findings for coronary heart disease and stroke.
A new study published in PLOS Medicine reveals that changes to the immune system occur rapidly after a traumatic injury, with levels of immune cells and molecules altered within minutes. The research aims to improve outcomes for patients who have suffered trauma by identifying those at risk of developing life-threatening complications.
Korean scientists report that ceria-zirconia nanoparticles act as effective scavengers of oxygen radicals, promoting a greatly enhanced surviving rate in sepsis model organisms. The nanoparticles accumulate in organs where severe immune responses occur and successfully eradicate reactive oxygen species.
A new portable device can quickly detect markers of deadly sepsis infection from a single drop of blood, providing rapid point-of-care measurement of the immune system's response. The device correlates well with traditional tests and vital signs, offering potential for earlier detection and prognosis.
A £1.5 million study led by the University of Warwick is investigating two biomarkers to guide safe reduction in antibiotic treatment time for patients with suspected sepsis. The trial will compare survival rates, discharge times, and antibiotic usage across three groups.
Researchers at Instituto Gulbenkian de Ciência found that controlling iron levels is crucial for maintaining vital organs' function during infection. They discovered ferritin's role in regulating glucose production, which prevents lethal sepsis outcomes.
A University of Pittsburgh-led study covering nearly 50,000 patients found that hospitals in New York State that followed the 'three-hour bundle' protocol for sepsis treatment had lower mortality rates. The protocol requires early identification and treatment within three hours of diagnosis, with completion averaging 1.3 hours.
Researchers have created a TaqMan-Based Multiplex real-time PCR detection system to rapidly diagnose sepsis, increasing the chance of targeting the correct agent and avoiding antibiotic misuse. The test detects 10 frequent bacterial pathogens from blood samples and can even identify pathogens in blood culture-negative cases.
A recent study found that patients with drug-resistant bacteria in their urine or stool samples have a significantly increased risk of developing drug-resistant sepsis. Researchers discovered that the risk is highest soon after detection and can persist for up to three years.
People taking oral corticosteroids for less than 30 days are at higher risk of broken bones, dangerous blood clots, and sepsis. Researchers call for better education on the potential risks and most appropriate uses of steroids.
A new biomarker called methylthioadenosine (MTA) has been identified as a predictor of death in sepsis patients. Measuring MTA levels can be approximately 80% accurate in predicting patient outcomes, similar to the APACHE II score.
Researchers found that a subgroup of NSAIDs also act strongly on another family of enzymes called caspases, which play a key role in aggressive immune responses like sepsis. The study suggests that these drugs could be repurposed to address other conditions and develop safer versions.
A risk prediction model developed by Kaiser Permanente has safely reduced antibiotic use in newborns by nearly 50%. The calculator uses data from over 600,000 babies to calculate the risk of early-onset sepsis and targets infants who are at highest risk for infection.
Researchers discovered a toxin from S. epidermidis that contributes to blood infections and worsens septic infection in mouse models. Clinical studies are needed to assess its impact on human sepsis.
Sepsis is a life-threatening organ malfunction caused by infection, associated with significant hospital deaths. Recognizing sepsis as a separate cause can lead to improved hygiene, nutrition, vaccination rates, and quality of life for those affected.
Researchers found that treating white blood cells with antibodies targeting PD-1 and PD-L1 molecules can restore their function and ability to kill bacteria. This discovery offers new hope for treating sepsis, a devastating inflammatory disease.
A study found that sepsis mortality rates are highest in regions with few trained intensivists, highlighting the need for increased critical care training programs. The authors suggest promoting critical care training and incentives to improve outcomes.
A prospective, randomised clinical trial found that an ultraviolet air steriliser significantly reduced sepsis and mortality in cardiac surgery patients. The study included 1097 patients and showed a lower rate of sepsis (3.4% vs 6.7%) and 30-day in-hospital mortality (3.8% vs 6.4%) in patients with the steriliser.
A new study published in Cell found that providing nutrients to mice with viral infections can help them survive, while those with bacterial infections die when fed. The researchers discovered that the brain's metabolic needs differ depending on the type of infection, which may have implications for designing clinical trials.
Researchers have identified a factor in umbilical cord blood that can counteract harmful inflammation and sepsis, with tripled survival rates in mice. The newly discovered factor, nNIF, is present for just two weeks after birth and may offer insights into controlling the inflammatory response.
Researchers found that a 40% reduction in sepsis deaths was achieved through simple steps, including increased training and a special observation chart. Standardized treatment plans can increase survival rates and reduce mortality from serious infections.
The NIH has selected winning teams from a nationwide undergraduate biomedical engineering design competition for their innovative solutions to various healthcare challenges. The designs showcased promising technologies for diagnosing diseases such as tuberculosis and sepsis, with potential to save millions of lives.
A new medical device that combines laser spectroscopy and precise flow measurement has shown promise in improving care for shock patients. The device, which fits into a standard ventilation tube, allows doctors to monitor oxygen consumption in real-time, potentially leading to more effective treatment.
A multidisciplinary team of UCSB faculty members and clinicians will conduct biomedical research on sepsis, a severe response to infections, thanks to a $12.8 million NIH grant. The program aims to develop radically different approaches to treating sepsis, with the goal of reducing disability and death.
Researchers discovered gut bacteria in the deepest reaches of failing lungs, which was previously thought to be an impossible environment for them. The more severe critical illness, the more gut bugs outnumbered usual lung bacteria.
Researchers at Boston Children's Hospital have discovered a new potential avenue for controlling severe bacterial infections and sepsis. The study reveals that a protein fragment called gasdermin-D-NT can kill both bacteria and infected cells, offering a defense against antibiotic-resistant infections.
Researchers at University of Birmingham develop test to predict sepsis in burn victims using biomarkers of neutrophil function. The test shows promise in identifying patients at risk of developing sepsis, a life-threatening condition that can be fatal if left untreated.
A novel on-chip microscope made from consumer electronics enables simultaneous measurement of nanometer-thick changes over a large volume in transparent objects. The device utilizes phase-shifting interferometry and offers unprecedented field-of-view and depth-of-field capabilities, making it suitable for point-of-care applications.
A rapid and specific diagnostic assay can detect pathogens in blood within an hour, distinguishing between infectious and non-infectious causes of inflammation. The assay uses FcMBL, a genetically engineered pathogen-binding protein, to identify infection-causing pathogens with high sensitivity and broad specificity.
The Wyss Institute aims to discover why some individuals tolerate infectious pathogens while others exhibit life-threatening responses, which could inform the development of novel therapies. The project will search for and identify examples of tolerance across several species through experiments with clinically-relevant pathogens.